Myriad Genetics, Inc. (MYGN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

TransMedics Group, Inc.

AtriCure, Inc.

PROCEPT BioRobotics Corp.

Veracyte, Inc.

Tandem Diabetes Care, Inc.

Alphatec Holdings, Inc.

NovoCure Ltd.

Myriad Genetics, Inc.

STAAR Surgical Co.

Pacific Biosciences of California, Inc.

Owens & Minor, Inc.

Why is Myriad Genetics, Inc. ?

Poor long term growth as Net Sales has grown by an annual rate of 1.64% and Operating profit at -14.04% over the last 5 years

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -53.81%, its profits have risen by 39.9%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -53.81% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Myriad Genetics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Myriad Genetics, Inc.

-53.11%

-0.91

87.50%

S&P 500

13.68%

0.71

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

1.64%

EBIT Growth (5y)

-14.04%

EBIT to Interest (avg)

-34.57

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.03

Sales to Capital Employed (avg)

1.14

Tax Ratio

20.09%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

0.41%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.15

EV to EBIT

-5.00

EV to EBITDA

-15.82

EV to Capital Employed

1.16

EV to Sales

0.50

PEG Ratio

Dividend Yield

ROCE (Latest)

-23.17%

ROE (Latest)

-16.68%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -2.2 MM

NET PROFIT(HY)

Higher at USD -41.2 MM

RAW MATERIAL COST(Y)

Fallen by -1.18% (YoY

-21What is not working for the Company

ROCE(HY)

Lowest at -72.52%

PRE-TAX PROFIT(Q)

At USD -26.2 MM has Fallen at -31.33%

DEBT-EQUITY RATIO (HY)

Highest at 17.95 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 9.06 times

INTEREST(Q)

Highest at USD 3.8 MM

NET PROFIT(Q)

Lowest at USD -27.4 MM

Here's what is working for Myriad Genetics, Inc.

Operating Cash Flow

Highest at USD -2.2 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Raw Material Cost

Fallen by -1.18% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Myriad Genetics, Inc.

Net Profit

At USD -27.4 MM has Fallen at -100.37%

over average net sales of the previous four periods of USD -13.67 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest

At USD 3.8 MM has Grown at 153.33%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Pre-Tax Profit

At USD -26.2 MM has Fallen at -31.33%

over average net sales of the previous four periods of USD -19.95 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Interest

Highest at USD 3.8 MM

in the last five periods and Increased by 153.33% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Net Profit

Lowest at USD -27.4 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Debt-Equity Ratio

Highest at 17.95 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 9.06 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio